| scholarly article | Q13442814 |
| P2093 | author name string | Ting Chen | |
| Leonid Kagan | |||
| Donald E Mager | |||
| P2860 | cites work | Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties | Q28261771 |
| Evaluation of rat intestinal absorption data and correlation with human intestinal absorption | Q30782163 | ||
| Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins | Q31135530 | ||
| Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats | Q34067981 | ||
| Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas | Q34234727 | ||
| Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats | Q34702329 | ||
| Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons | Q35223673 | ||
| Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans | Q35913076 | ||
| Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept | Q37437579 | ||
| Subcutaneous administration of biotherapeutics: current experience in animal models. | Q37777105 | ||
| Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. | Q39732229 | ||
| Interspecies scaling: predicting clearance of drugs in humans. Three different approaches | Q41189275 | ||
| Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. | Q41527377 | ||
| Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline | Q42163303 | ||
| Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin | Q42651441 | ||
| Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas | Q42821767 | ||
| Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. | Q43259882 | ||
| Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro | Q43586628 | ||
| General pharmacokinetic model for drugs exhibiting target-mediated drug disposition | Q43985366 | ||
| Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys | Q44378873 | ||
| Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. | Q45257473 | ||
| Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes | Q46689486 | ||
| Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration | Q46740431 | ||
| GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting | Q48180523 | ||
| Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling | Q48732028 | ||
| Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. | Q50691148 | ||
| Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. | Q51963868 | ||
| Animal scale-up | Q52727774 | ||
| Investigation of exenatide elimination and its in vivo and in vitro degradation. | Q53621094 | ||
| Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2 | Q58449146 | ||
| Subcutaneous erythropoietin therapy: comparison of three different sites of injection | Q70168378 | ||
| Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary | Q70957825 | ||
| Fluorescein-Trp25-exendin-4, a biologically active fluorescent probe for the human GLP-1 receptor | Q73335644 | ||
| GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro | Q73444367 | ||
| Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase | Q73621912 | ||
| Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys | Q80459338 | ||
| Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry | Q83763229 | ||
| Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats | Q84879198 | ||
| Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels | Q95792109 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 751-760 | |
| P577 | publication date | 2012-11-15 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Interspecies modeling and prediction of human exenatide pharmacokinetics | |
| P478 | volume | 30 |
| Q38707493 | A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development |
| Q42351659 | A Tutorial on Target-Mediated Drug Disposition (TMDD) Models |
| Q90457974 | Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats |
| Q38805958 | Input Estimation for Extended-Release Formulations Exemplified with Exenatide |
| Q42428917 | Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats |
| Q41066240 | Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion |
| Q41812080 | Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats |
| Q37639905 | Population pharmacokinetics of exenatide |
| Q38264736 | Strategic approaches to optimizing peptide ADME properties |
| Q47625727 | The Food Environment, Preference, and Experience Modulate the Effects of Exendin-4 on Food Intake and Reward. |
| Q96954316 | Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS |
Search more.